Browsing Tag
Jacob Van Naarden
5 posts
Lilly bets up to $2.3bn on Ajax Therapeutics to crack the resistant myelofibrosis market with a Type II JAK2 inhibitor
Lilly is paying up to $2.3B for Ajax Therapeutics' Type II JAK2 inhibitor. The real question is whether it can crack Incyte's Jakafi grip on myelofibrosis.
Why Lilly’s $3.25bn Kelonia acquisition signals a manufacturing shift across the entire CAR-T landscape
Eli Lilly agrees to acquire Kelonia Therapeutics for up to $7B. What the iGPS in vivo CAR-T platform means for oncology and LLY investors. Read the analysis.
Eli Lilly and Company completes $1.4bn acquisition of POINT Biopharma
Eli Lilly and Company (NYSE: LLY) has announced the successful completion of its $1.4 billion acquisition of POINT…
Eli Lilly announces $1.4bn acquisition of POINT Biopharma in radiopharmaceutical domain
Eli Lilly and Company (NYSE: LLY) is set to acquire POINT Biopharma Global, Inc. (NASDAQ: PNT), a leading…
Lilly gets Jaypirca FDA approval for mantle cell lymphoma
Loxo@Lilly, the oncology division of Eli Lilly and Company (Lilly), has secured the accelerated approval of the US…